ID: ALA579882

Max Phase: Preclinical

Molecular Formula: C21H22N4O4S

Molecular Weight: 426.50

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (2): TCMDC-124310 | TCMDC-124310
Synonyms from Alternative Forms(2):

    Canonical SMILES:  O=C(Nc1ccc(S(=O)(=O)N2CCCCC2)cc1)c1cc(-c2ccccc2O)n[nH]1

    Standard InChI:  InChI=1S/C21H22N4O4S/c26-20-7-3-2-6-17(20)18-14-19(24-23-18)21(27)22-15-8-10-16(11-9-15)30(28,29)25-12-4-1-5-13-25/h2-3,6-11,14,26H,1,4-5,12-13H2,(H,22,27)(H,23,24)

    Standard InChI Key:  VHYUALWDIXAVIZ-UHFFFAOYSA-N

    Associated Targets(Human)

    HepG2 196354 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Ras-related C3 botulinum toxin substrate 1 221 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Transforming protein RhoA 190 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Glucose transporter 14755 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    D-3-phosphoglycerate dehydrogenase 883 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Plasmodium falciparum 966862 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Hexose transporter 1 14071 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Glucose transporter 14035 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 426.50Molecular Weight (Monoisotopic): 426.1362AlogP: 3.21#Rotatable Bonds: 5
    Polar Surface Area: 115.39Molecular Species: NEUTRALHBA: 5HBD: 3
    #RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
    CX Acidic pKa: 8.66CX Basic pKa: 1.13CX LogP: 2.92CX LogD: 2.90
    Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.58Np Likeness Score: -1.86

    References

    1. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF..  (2010)  Thousands of chemical starting points for antimalarial lead identification.,  465  (7296): [PMID:20485427] [10.1038/nature09107]
    2. Ferri N, Bernini SK, Corsini A, Clerici F, Erba E, Stragliotto S, Contini A.  (2013)  3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors,  (3): [10.1039/C2MD20328F]
    3. St. Jude Leishmania screening dataset.,  [10.6019/CHEMBL3433997]
    4. Ravez S, Spillier Q, Marteau R, Feron O, Frédérick R..  (2017)  Challenges and Opportunities in the Development of Serine Synthetic Pathway Inhibitors for Cancer Therapy.,  60  (4): [PMID:27959531] [10.1021/acs.jmedchem.6b01167]
    5. Zhao JY, Feng KR, Wang F, Zhang JW, Cheng JF, Lin GQ, Gao D, Tian P..  (2021)  A retrospective overview of PHGDH and its inhibitors for regulating cancer metabolism.,  217  [PMID:33756126] [10.1016/j.ejmech.2021.113379]